Scientific Program

09:15-09:55 Plenary 1: siRNA Therapeutics
09:15-09:55 PL01 Mano Manoharan (Alnylam Pharmaceuticals, USA)
09:55-11:10 Session 1. siRNA Therapeutics
09:55-10:20

S01-1 Development of New Molecular Technologies for siRNA Therapeutics

Takeshi Wada (Tokyo University of Science, Japan)
10:20-10:45

S01-2 Harnessing the Promise of RNA Therapeutics

Jihye Park (Novo Nordisk, USA)
10:45-11:10

S01-3 Expanding RNAi Therapeutics Beyond the Liver: An Integrated OASIS Platform for Hepatic and Extrahepatic Delivery

June Hyun Park (OliX Pharmaceuticals, Korea)
11:30-12:35 Session 2. mRNA Therapeutics: Innovation & Production
11:30-11:55

S02-1 Chemical Synthesis and Engineering of mRNA for Next-Generation Nucleic Acid Therapeutics

Hiroshi Abe (Nagoya University, Japan)
11:55-12:20

S02-2 Transforming Pulmonary Therapeutics with a Novel Lung-Selective Ionizable Lipid and Polymer-Based Stability Enhanced Nanoshell (SENSTM) Technology Optimized for Inhaled and Systemic Administrations

Helen Cho (Samyang Biopharm, Korea)
12:20-12:35

S02-3 Chemical Engineering of mRNA for Enhanced Translation and Therapeutic Performance

Young Jun Seo (Elonova, Korea)
12:35-13:35 Lunch Seminar 1 [LS1]
12:35-13:35 LS1 TBD
13:35-14:15 Plenary 2: RNA Biology
13:35-14:15

PL02 Noncanonical Tails: Functions, Mechanisms, and Therapeutic Potential

V. Narry Kim (Seoul National University / IBS, Korea)
14:15-15:35 Session 3. RNA Biology & Chemistry
14:15-14:40

S03-1 Potent and Specific siRNA Design: From Sequence Rules to Structure-Guided Precision Therapeutics

Kumiko Ui-Tei (Institute of Science Tokyo, Japan)
14:40-15:05 S03-2 TBD
15:05-15:20

S03-3 Decoding RNA-RBP Dynamics to Control RNA Immunogenicity

Yoosik Kim (KAIST, Korea)
15:20-15:35

S03-4 Synthesis and Biological Evaluation of 3′-C-Fluoromethyl-8-azaadenosine as a Novel Hit Targeting ADAR-Mediated RNA Editing

Jinha Yu (Ewha Womans University, Korea)
15:55-17:25 Session 4. Innovation in Oligonucleotide Therapeutics
15:55-16:20 S04-1 Ron Batra (Dyne Therapeutics, USA)
16:20-16:45

S04-2 RNAa: From Bench to Bedside—A 20-Year Journey

Long-Cheng Li (Ractigen Therapeutics, China)
16:45-17:10

S04-3 Engineered Cysteine AOC Process Development: DAR Control, Orthogonal Analytics, and Site-Level Characterisation

Kris S. Choi / Mahnseok Kye (ST Pharm, Korea)
17:10-17:25

S04-4 Extrahepatic Delivery of Oligonucleotide Therapeutics Using DNA Nanostructures

Dae-Ro Ahn (KIST, Korea)
TOP